PFE · News · 20260903N
Licensing / Collaboration Deals
PFIZER INC · 2026-09-03 · Importance 52 · Surprise 42 · In source text
Pfizer granted Medicus Pharma an exclusive, sublicensable global license for PF-08046031, also known as CD228V. The early clinical-stage antibody-drug conjugate targets melanotransferrin and is intended for oncology development. The transaction is valued at more than $1 billion and covers development, manufacturing, and commercialization rights. Pfizer will retain economic interests and future options while externalizing development costs and pipeline risk.
Key facts
- The Medicus Pharma licensing deal for PF-08046031 (CD228V) from Pfizer was reported as worth over $1 billion. source
- Medicus Pharma secured an exclusive, sublicensable global license from Pfizer to develop, manufacture, and commercialize PF-08046031 (CD228V). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | The Medicus Pharma licensing deal for PF-08046031 (CD228V) from Pfizer was reported as worth over $1 billion. |